Skip to content
PreclinicalResearch compound

5‑Amino‑1MQ

Experimental metabolism-boosting compound that blocks the enzyme NNMT: switching the enzyme off sped up metabolism in mice, not studied in humans.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

5-Amino-1MQ vial

DETAILED OVERVIEW

What is 5-Amino-1MQ?

5-Amino-1MQ is an experimental compound that blocks an enzyme called NNMT, aiming to speed up metabolism. It has not been approved as a medicine anywhere, and for a few years it has been sold online as a research chemical.

In obesity, this enzyme is more active than usual in fat tissue and the liver. In mice in which the enzyme was switched off, metabolism ran faster, insulin sensitivity improved and fat cells became smaller; the compound tries to copy this effect with a drug. It has not been studied in humans, so its effects and safety are unknown. Products sold online may differ from the label and may be contaminated. It must not be used in pregnancy or breastfeeding, because nothing is known about its effects then. It is not listed separately on the anti-doping list, but the general ban on unapproved substances means it can lead to a sanction in competitive sport.

Mechanism

NNMT enzyme blocker; laboratory and animal data only

Half-life

About 4–8 hours (estimated from mice); no human measurement

Onset

In mice metabolism sped up within weeks; unknown in humans

Legal status

FDA never approved; EU EMA never approved; research-chemical underground market only. WADA NOT explicitly listed, but 'S0 catch-all non-approved substance' category may apply.

Data console

Lab data

Androgenic:AnabolicN/A (not AAS, NNMT inhibitor)
AR bindingNNMT IC50 ~1.6 μM (Neelakantan 2018 PMID 28425865…
Active half-lifeESTIMATED ~4-8h (NO human PK data)
Detection windowWADA-accredited detection protocol NOT specifically regulated (5-Amino-1MQ NOT explicitly listed). Out-of-competition LC-MS/MS possible under 'S0 catch-all' category.
AromatizationDoes not aromatize (not a steroid – designer methylquinoline, NNMT inhibitor). No CYP19 interaction.
HepatotoxicityUnknown – research chemical / preclinical only, long-term human data is lacking. Preclinical mouse-model 4-8 week chronic dose did NOT significantly elevate liver enzymes (ALT/AST) (Kraus 2014 PMID 24622204 supplementary data), but human extrapolation is NOT proven.

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No established human side-effect profile – preclinical-only NNMT inhibitor with no Phase I/II/III human trials, so the full safety window (PK, NOAEL, LD50) is unknown.
  • Research-chemical sourcing risk: label-claim discrepancy and HPLC-untested content – the product may contain the wrong dose, contaminants, or a different molecule (25–30% of analogous online products did not match their label).
  • Possible gastrointestinal discomfort with oral (capsule) use (nausea, stomach upset), which taking with food or more fluid may ease – not clinically validated, anecdote-level only.
  • Theoretical disruption of NAD+/methyl-donor metabolism: NNMT inhibition shifts SAM-pool and cellular NAD+ balance – the long-term metabolic consequence in humans is unknown.
  • Unknown hepatic and renal impact: human liver- and kidney-dependent clearance is uncharacterised, so organ burden and accumulation risk cannot be estimated (in preclinical mouse data ALT/AST did not rise significantly, but this does not extrapolate to humans).
  • Unknown drug interactions: a presumed overlap exists with agents acting on NAD+/AMPK/metabolic pathways (e.g. nicotinamide riboside, metformin), but no clinical interaction data exist.

Contraindications · 6

  • Pregnancy and breastfeeding – absolute contraindication (no reproductive toxicology or teratogenicity data in humans).
  • Any human-consumption context in general – preclinical-only agent with no safe human protocol; intended only for in-vitro/animal research use.
  • Pre-existing liver disease – relative contraindication (human hepatic clearance is unknown and the burden cannot be estimated).
  • Pre-existing kidney disease – relative contraindication (human renal elimination and accumulation risk are unknown).
  • Competitive athletes subject to testing – potential sanction under the WADA 'S0 non-approved substance' clause (the agent was never approved by the FDA/EMA); to be avoided.
  • Minors – categorically to be avoided (no human safety data; effect on developing metabolism unknown).

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about 5‑Amino‑1MQ?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.